Applied Biosystems & Celera Genomics Fourth Quarter and Year-end FY 2004 Financial Results and Conference Call Scheduled For July 28, 2004
NORWALK, CT - July 13, 2004
Applera Corporation announced today that it will issue fiscal 2004 fourth quarter and full year results for Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA) on Wednesday, July 28, 2004. Results are scheduled for release before the opening of trading on the New York Stock Exchange.
Tony L. White, Chief Executive Officer, Dennis L. Winger, Chief Financial Officer of Applera Corporation, and senior managers from the Corporation’s businesses will lead a conference call the same day at 11:00 a.m. (EDT) to discuss these results and other matters related to the businesses. The call will be formatted to focus on each of the Applera businesses separately, approximately at the times indicated below, although the exact timing may be different as the call will proceed without pause between segments:
Applied Biosystems Group 11:00 a.m. (EDT)
Celera Diagnostics 12:00 p.m.
Celera Genomics Group 12:15 p.m.
During each segment, the management team will make prepared remarks and answer questions from securities analysts and investment professionals. Investors, securities analysts, representatives of the media and other interested parties who would like to participate should dial 706.634.4992 (code "Applera") at any time from 10:45 a.m. until the end of the call. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit www.applera.com and go to the "Investors & Media" section of the web site, or www.celera.com and go to the "Investors & Media" section, or www.appliedbiosystems.com and go to the “Investors” section. A digital recording will be available approximately two hours after the completion of the conference call on July 28 until August 8, 2004. Interested parties should call 706.645.9291 and enter conference ID 8716436.
About Applera Corporation
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2003. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics. Its Celera Discovery SystemTM online platform, marketed exclusively by Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923.
Copyright © 2004. Applera Corporation. All Rights Reserved. Applied Biosystems, Celera, Celera Diagnostics and Celera Genomics are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and certain other countries.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.